Value investing, at its core, is about finding companies whose market price doesn't fully reflect their underlying worth. Pioneered by Benjamin Graham and famously practiced by Warren Buffett, the strategy focuses on buying stocks that appear undervalued relative to their intrinsic value, providing a "margin of safety" against unforeseen downturns. While the broader market, with the S&P 500 trending positively in both the long and short term, often chases growth at any price, patient investors can find opportunities in high-quality businesses trading at a discount. Our latest screen applies this logic by filtering for companies that have a strong fundamental valuation rating (above 7/10) while maintaining decent scores in profitability, health, and growth—a combination that often signals a potential value play.
Valuation: A Key Pillar of Value Investing
For a value investor, the valuation metrics are the starting point, and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) scores an impressive 8 out of 10 in this category. This is crucial because, as Graham taught, buying with a margin of safety begins with identifying a gap between price and value.
The company's high trailing Price/Earnings (P/E) ratio of 43.06 might initially alarm some investors. However, when compared to its peers, a different picture emerges. Within the often richly-valued Biotechnology industry, BMRN is actually cheaper than 92.38% of its competitors. More importantly, the forward P/E ratio drops substantially to 10.27, suggesting that analysts expect earnings to ramp up significantly.
- Price/Forward Earnings (10.27): This is a standout figure. BMRN trades at a lower forward P/E than 97.46% of its industry peers and is also well below the S&P 500's average forward P/E of 21.49.
- EV/EBITDA & P/FCF Ratios: The story holds across other valuation proxies. Based on Enterprise Value to EBITDA, BMRN is cheaper than 94.92% of its industry. Similarly, its Price to Free Cash Flow ratio is lower than 96.88% of the sector, reinforcing that on multiple fronts, the market may be undervaluing the company's future cash-generating ability.
Profitability & Health: A Foundation of Safety
A value stock isn't just cheap; it must be a good business. This is where BMRN’s fundamental strengths shine, earning a Profitability rating of 8/10 and a Health rating of 7/10. These high scores provide the financial stability and earnings power that value investors seek as a buffer.
- Profitability: The company shows strong operational efficiency. Its Operating Margin of 23.98% and Gross Margin of 80.21% both rank in the top 15% of its industry. The Return on Invested Capital (ROIC) of 7.53% also outperforms 93.16% of peers, indicating that the company is effectively turning capital into profits.
- Health: Financial strength is paramount for weathering any market storm. BMRN shows impressive solvency. Its Altman-Z score of 4.13 points to a low risk of bankruptcy. The company carries a manageable debt level, with a Debt to FCF ratio of just 1.88, meaning it could theoretically pay off all its debt in less than two years using its free cash flow. Furthermore, a Current Ratio of 5.81 ensures excellent short-term liquidity.
Growth: The Catalyst for Future Value
While value investing looks at the present, it also requires a view of the future. An undervalued stock with no growth prospects can be a "value trap." BMRN’s Growth rating of 6 out of 10 is decent, but the future outlook is particularly compelling from a value perspective.
The current earnings picture shows a past decline (EPS has fallen by -17.11% on average per year), which partly explains why the stock may be out of favor. However, analysts anticipate a major reversal. The Expected EPS Growth is a staggering 58.99% per year going forward, which is a very strong acceleration. When you factor this growth into the valuation, the low PEG Ratio (NY) confirms that the stock is currently being priced for stagnation, not the impending growth spurt. This combination—a cheap current valuation paired with a strong growth turnaround—is exactly the type of scenario value investors look for to benefit from both earnings expansion and multiple expansion.
Analyst Views
The full fundamental analysis report for BMRN assigns the company an overall rating of 7 out of 10. The summary correctly notes that while the market currently has a tepid view, the fundamentals are strong: "Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidity or solvency issues. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth. With these ratings, BMRN could be worth investigating further for value and quality investing!"
Screening for More Value Opportunities
BioMarin Pharmaceutical represents a single example of how a structured screen can uncover potential value plays. By combining a strong valuation rating with above-average fundamentals in profitability, health, and growth, investors can systematically find companies that are not just cheap, but also financially sound with a path to recovery.
You can run this exact screening process yourself to find more candidates. Click here to access the full 'Decent Value' stock screen and explore other companies that fit this criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Past performance and fundamental analysis scores are not a guarantee of future results. Always conduct your own research before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating
Value investing, at its core, is about finding companies whose market price doesn't fully reflect their underlying worth. Pioneered by Benjamin Graham and famously practiced by Warren Buffett, the strategy focuses on buying stocks that appear undervalued relative to their intrinsic value, providing a "margin of safety" against unforeseen downturns. While the broader market, with the S&P 500 trending positively in both the long and short term, often chases growth at any price, patient investors can find opportunities in high-quality businesses trading at a discount. Our latest screen applies this logic by filtering for companies that have a strong fundamental valuation rating (above 7/10) while maintaining decent scores in profitability, health, and growth—a combination that often signals a potential value play.
Valuation: A Key Pillar of Value Investing
For a value investor, the valuation metrics are the starting point, and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) scores an impressive 8 out of 10 in this category. This is crucial because, as Graham taught, buying with a margin of safety begins with identifying a gap between price and value.
The company's high trailing Price/Earnings (P/E) ratio of 43.06 might initially alarm some investors. However, when compared to its peers, a different picture emerges. Within the often richly-valued Biotechnology industry, BMRN is actually cheaper than 92.38% of its competitors. More importantly, the forward P/E ratio drops substantially to 10.27, suggesting that analysts expect earnings to ramp up significantly.
Profitability & Health: A Foundation of Safety
A value stock isn't just cheap; it must be a good business. This is where BMRN’s fundamental strengths shine, earning a Profitability rating of 8/10 and a Health rating of 7/10. These high scores provide the financial stability and earnings power that value investors seek as a buffer.
Growth: The Catalyst for Future Value
While value investing looks at the present, it also requires a view of the future. An undervalued stock with no growth prospects can be a "value trap." BMRN’s Growth rating of 6 out of 10 is decent, but the future outlook is particularly compelling from a value perspective.
The current earnings picture shows a past decline (EPS has fallen by -17.11% on average per year), which partly explains why the stock may be out of favor. However, analysts anticipate a major reversal. The Expected EPS Growth is a staggering 58.99% per year going forward, which is a very strong acceleration. When you factor this growth into the valuation, the low PEG Ratio (NY) confirms that the stock is currently being priced for stagnation, not the impending growth spurt. This combination—a cheap current valuation paired with a strong growth turnaround—is exactly the type of scenario value investors look for to benefit from both earnings expansion and multiple expansion.
Analyst Views
The full fundamental analysis report for BMRN assigns the company an overall rating of 7 out of 10. The summary correctly notes that while the market currently has a tepid view, the fundamentals are strong: "Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidity or solvency issues. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth. With these ratings, BMRN could be worth investigating further for value and quality investing!"
Screening for More Value Opportunities
BioMarin Pharmaceutical represents a single example of how a structured screen can uncover potential value plays. By combining a strong valuation rating with above-average fundamentals in profitability, health, and growth, investors can systematically find companies that are not just cheap, but also financially sound with a path to recovery.
You can run this exact screening process yourself to find more candidates. Click here to access the full 'Decent Value' stock screen and explore other companies that fit this criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Past performance and fundamental analysis scores are not a guarantee of future results. Always conduct your own research before making any investment decisions.
Read full article here »